- Home
- CSQ vs DNLI Comparison
CSQ vs DNLI Comparison
Compare CSQ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | DNLI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CSQ | DNLI |
|---|---|---|
| Price | $19.28 | $21.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $31.58 |
| AVG Volume (30 Days) | 220.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,975.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $10.57 |
| 52 Week High | $16.45 | $24.35 |
Technical Indicators
Market Signals| Indicator | CSQ | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 68.53 |
| Support Level | $19.27 | $20.35 |
| Resistance Level | $19.54 | $21.39 |
| Average True Range (ATR) | 0.22 | 1.14 |
| MACD | -0.02 | 0.38 |
| Stochastic Oscillator | 42.77 | 92.05 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.